Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome. Issue 22 (20th November 2022) - Fan, Lina; Li, Lei; Gao, Liying; Hu, Yue; Yu, Aiping; Zhang, Defa; Qiu, Chunting; Huang, Rong; Wu, Yue; Ma, Ping